anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The patients in this group will be treated with standard triple therapy only. The standard triple therapy consists of amoxicillin oral tablet 50 mg/kg/d and clarithromycin oral tablet 15 mg/kg/d twice daily for 14 days, and omeprazole 1 mg/kg/d once daily for a month.
OBJECTIVE: Chronic low back pain (CLBP) is a prevalent health condition worldwide. Several therapeutic interventions aim to improve CLBP. Pain Neuroscience Education (PNE) helps patients better understand their pain from biological and physiological perspectives, which clinicians use to reduce pain and disability in patients with chronic musculoskeletal conditions. Neuromuscular exercises (NMS) are also treatments adopted in CLBP. This study will investigate whether PNE combined with an NMS program improves pain, functional and psychological outcomes more than NMS alone in patients with CLBP.
METHODS: In this single-blind randomized controlled trial, 60 patients (male and female; age range, 30-60 years) diagnosed with CLBP will be randomly assigned to one of the following groups: (1) PNE plus NMS (n = 30; 24 sessions of PNE plus NMS in a total of 8 weeks, 3 each week), and (2) NMS alone (n = 30; 24 sessions of NMS sessions in a total of 8 weeks, 3 each week). Outcome assessors will be blinded to the group allocation. The primary outcome will be pain. Secondary outcomes will be disability, fear-avoidance beliefs about work and physical activity, self-efficacy, exercise anxiety, and kinesiophobia. Outcomes will be assessed at baseline, after 8 weeks of intervention, and 6 months post-intervention.
DISCUSSION: The findings of this RCT will help shed light on new treatment strategies to address the biopsychosocial dimensions of CLBP. The study protocol will be conducted in a clinical setting, offering the opportunity for future implementation in healthcare systems. Moreover, it will help clarify whether a combined treatment (PNE with NMS) is more effective than NMS alone for improving pain, functional and psychological outcomes in CLBP.
TRIAL REGISTRATION: Study registration: The study was prospectively registered in the Iranian Registry of Clinical Trials-IRCT20190427043384N2 (https://www.irct.ir/trial/69146). Registered on March 17, 2023.
The invention relates to a fruit vinegar for clearing heat and moistening the intestines and a preparation method of the fruit vinegar, belonging to the technical field of traditional Chinese medicines. The fruit vinegar uses Chinese wolfberry fruits, cassia seeds, senna leaves, lotus plumules, honeysuckle flowers, wild chrysanthemum flowers and hawthorn fruits as main materials, and is prepared through the following 11 steps: cleaning, decoction, enzyme treatment, clarification, alcoholic fermentation, acetic fermentation, aging, filtration, stabilization treatment, ultrafiltration, and preparation. The method is simple in technique. The produced fruit vinegar is rich in nutrition and good in taste, with the functions of clearing heat and detoxifying, moisten the intestines and unblock the bowels, and promoting metabolism. The fruit vinegar is significantly effective in treating constipation. There is no toxic side effect for people to drink the fruit vinegar in long term.
This invention provides an H9N2 avian influenza virus strain. The avian influenza virus strain is an rH9N2-2/6 virus strain recombined with HA protein of a SEQ.NO.2 protein sequence and NA protein of a SEQ ID No:4 protein sequence. A reverse genetics technology is utilized to save the recombinant H9N2 avian influenza virus rH9N2-2/6 virus strain with good immunogenicity. After 28d of immunization by the inactivated vaccine prepared by the virus strain, the HI antibody reaches 11Log2. The reverse genetics technology involved in the invention can quickly acquire the target virus, and the screened virus can be used for preparation of a vaccine preventing broad-spectrum viruses. Immunization by the vaccine can provide complete protection against H9N2 attack.
Insomnia, characterized by an inability to initiate and maintain sleep, is a defining feature of mood disorders such as depression. CBT has been found to be an effective treatment for depression-related insomnia. This study will determine the effectiveness of CBT in treating insomnia that is secondary to depression. In addition, this study will assess the relationship between insomnia and depression, since previous studies have shown that insomnia may not only be a symptom of depression but may also indicate the onset of a depressive episode.

Participants will be randomly assigned to receive weekly sessions of either CBT or clinician monitoring for 8 weeks. Participants in both groups will meet with a therapist at selected visits, but only CBT participants will receive actual therapy. All participants will have 13 study visits; four will be overnight visits in a sleep lab. On Visit 1, participants will complete questionnaires about their sleep quality and symptoms of depression. Participants will also undergo a physical exam and will begin a daily sleep diary. Visits 2, 3, 12, and 13 will be overnight visits in the sleep lab. During these visits, participants will have electrodes placed on their bodies and a polysomnograph will be used to monitor their sleep. Participants will meet with their therapist on Visits 4 to 11. Participants' sleep diaries, depression scales, and sleep scales will be used for assessment. After the intervention part of the study is complete, participants will have monthly follow-up visits for up to 2 years. During the follow-up visits, participants will complete questionnaires about their sleep quality and symptoms of depression.
Administration of ketorolac 0.5 mg/kg up to 10 mg, one single dose at the enrollment. This group will receive also a placebo indistinguishable from the ibuprofen.
The study assesses the feasibility of an advanced prosthesis control system aimed at development of a more intuitive and functional prosthetic device. Tiny (2.5 mm by 16 mm) Implantable Myoelectric Sensors (IMES) will be implanted into the residual forearm muscles of three transradial amputee subjects. These devices wirelessly transmit electrical muscle signals to an electromechanical prosthetic wrist and hand.

Following a two-week recovery from implantation of six to eight IMES into residual forearm muscles, subjects will initiate seven months of training. Subjects first train for approximately a month using a bench-top IMES system. When they receive their custom-fit IMES Prosthesis (including electromechanical wrist and hand) subjects initiate six months of additional training. Subjects will then be given the option to use the IMES Prosthesis for another sixteen months. The usability and functionality of the prosthetic system will be evaluated throughout the study.
Treatable traits is a personalized medicine approach to the management of airway disease. Assessing traits within the 3 domains of pulmonary, extrapulmonary, and behavioral/lifestyle/risk factor traits, and applying targeted treatments to effectively manage these traits, enables a holistic and personalized approach to care. Asthma is a heterogeneous and complex airway disease that is frequently complicated by several extrapulmonary traits that impact asthma outcomes and predict future outcomes. We propose that the identification of extrapulmonary and behavioral risk factor traits and the implementation of targeted therapy will lead to improved management of people with asthma. Furthermore, many extrapulmonary traits present as "connected comorbidities"; that is, they coexist with asthma, have an impact on asthma, and effective treatment improves both asthma and the comorbidity or the comorbidities may share a similar mechanism. In this review, we explore this concept and look at atopic dermatitis, chronic rhinosinusitis with nasal polyps, gastroesophageal reflux disease, anxiety, and depression as treatable traits of asthma and how these can be managed using this approach.
Patients receive ubidecarenone injectable nanosuspension IV over 72 hours twice weekly. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
A medical system comprising a first medical device, a second medical device, and a computer. The first medical device is configured to be placed beneath the dermis. The first medical device comprises an enclosure comprising non-electrically conductive material. A cap couples to the enclosure and is configured to seal the enclosure. The enclosure houses electronic circuitry configured to measure one or more parameter or provide a therapy. The cap couples to the ground of the electronic circuitry. The first medical device includes a dual band antenna. A first antenna is configured to operate within a first frequency band below 1 gigahertz. The second antenna is configured to operate at a frequency above 1 gigahertz. The second medical device is configured to transmit a radio frequency signal to the first medical device. The first medical device is configured to harvest the energy received from the radio frequency signal to enable the electronic circuitry and perform at least one task.
Women who agree to enrollment will undergo our intervention, which will include an educational intervention and free on-site provision of all reversible contraceptive options, including LARC. This educational 5 intervention will be a one-on-one educational session on all available methods of contraception, with an emphasis on the safety and efficacy of long-acting reversible contraception (LARC) and the importance of planning a pregnancy in women with medical conditions requiring anticoagulation. A provider (clinic officer, nurse or physician) trained in family planning counseling and provision will provide all counseling and discussions in Kiswahili. Women will then be offered free, on-site provision of whichever contraceptive method they choose by a trained provider.
The prevalence of heart failure with preserved ejection fraction (HFpEF) accounts for approximately 50% of the total heart failure population, and with the aging of the population and the increasing prevalence of hypertension, obesity, and type 2 diabetes (T2DM), the incidence of HFpEF continues to rise and has become the most common subtype of heart failure. Compared with heart failure with reduced ejection fraction, HFpEF has a more complex pathophysiology and is more often associated with hypertension, T2DM, obesity, atrial fibrillation, renal insufficiency, pulmonary hypertension, obstructive sleep apnea, and other comorbidities. HFpEF has generally been considered a syndrome with high phenotypic heterogeneity, and no effective treatments have been shown to reduce mortality to date. Diuretics and comorbidity management are traditional treatments for HFpEF; however, they are mostly empirical due to a lack of clinical evidence in the setting of HFpEF. With the EMPEROR-Preserved and DELIVER results, sodium-glucose cotransporter 2 inhibitors become the first evidence-based therapies to reduce rehospitalization for heart failure. Subgroup analyses of the PARAGON-HF, TOPCAT, and CHARM-Preserved trials suggest that angiotensin receptor-neprilysin inhibitors, spironolactone, and angiotensin II receptor blockers may be beneficial in patients at the lower end of the ejection fraction spectrum. Other potential pharmacotherapies represented by non-steroidal mineralocorticoid receptor antagonists finerenone and antifibrotic agent pirfenidone also hold promise for the treatment of HFpEF. This article intends to review the clinical evidence on current pharmacotherapies of HFpEF, as well as the comorbidities management of atrial fibrillation, hypertension, T2DM, obesity, pulmonary hypertension, renal insufficiency, obstructive sleep apnea, and iron deficiency, to optimize the clinical management of HFpEF.
Balance impairment is associated gait dysfunction with several quantitative spatiotemporal gait parameters in patients with stroke. However, the link between balance impairments and joint kinematics during walking remains unclear. Clinical assessments and gait measurements using motion analysis system was conducted in 44 stroke patients. This study utilised principal component analysis to identify key joint kinematics characteristics of patients with stroke during walking using average joint angles of pelvis and bilateral lower limbs in every gait-cycle percentile related to balance impairments. Reconstructed kinematics showed the differences in joint kinematics in both paretic and nonparetic lower limbs that can be distinguished by balance impairment, particularly in the sagittal planes during swing phase. The impaired balance group exhibited greater joint variability in both the paretic and nonparetic limbs in the sagittal plane during entire gait phase and during terminal swing phase respectively compared with those with high balance scores. This study provides a more comprehensive understanding of stroke hemiparesis gait patterns and suggests considering both nonparetic and paretic limb function, as well as bilateral coordination in clinical practice. Principal component analysis can be a useful assessment tool to distinguish differences in balance impairment and dynamic symmetry during gait in patients with stroke.
Compositions containing biologically active molecules encapsulated in self-assembling, diketopiperazine microspheres (TECHNOSPHEREsTM) and methods for making and administering such compositions are described herein. The compositions can be used to immunize individuals against agents of biological warfare. The biologically active molecules include atropine, antibodies, antigens, and antibiotics. The compositions can be placed in an inhalation device for self-administration. Pulmonary delivery of TECHNOSPHERETM encapsulated atropine, antibodies, vaccines, and antibiotics provides an accelerated onset of immunity to the targeted disease. Furthermore, the TECHNOSPHERETM encapsulated atropine, antibodies, vaccines, and antibiotics are stable formulations, suitable for stockpiling, rapid dissemination and mass treatment.
Patients receive RSHF according to : 30 Gy in 5 fractions of 6 Gy spaced 48 hours or 27 Gy in 3 fractions of 9 Gy spaced 48 hours or 20 Gy in 1 fraction. combined with zoledronic acid (4 mg IV slow monthly for 12 months, dose adjusted according to creatinine clearance).
Theory lecture EGD. Three hours simulator training for EGD. 60 minutes supervised training. Supervised endoscopy. Theory lecture Colonoscopy. Three hours simulator training for Colonoscopy. 60 minutes supervised training. Supervised endoscopy. Group will be followed up for 4 weeks training time.
For most patients, the recommended starting dose for Venlafaxine Hydrochloride Extended-release Capsules is 75 mg per day, administered in a single dose. For some patients, it may be desirable to start at 37.5 mg per day for 4 to 7 days to allow new patients to adjust to the medication before increasing to 75 mg per day. Patients not responding to the initial 75 mg per day dose may benefit from dose increases to a maximum of 225 mg per day. Dose increases should be in increments of up to 75 mg per day, as needed, and should be made at intervals of not less than 4 days, since steady-state plasma levels of venlafaxine and its major metabolites are achieved in most patients by day 4 [see Clinical Pharmacology (12.3)]. In the clinical studies establishing efficacy, upward titration was permitted at intervals of 2 weeks or more.

  


It should be noted that, while the maximum recommended dose for moderately depressed outpatients is also 225 mg per day for Venlafaxine Hydrochloride (immediate-release) Tablets, more severely depressed inpatients in one study of the development program for that product responded to a mean dose of 350 mg per day (range of 150 to 375 mg per day). Whether or not higher doses of Venlafaxine Hydrochloride Extended-release Capsules are needed for more severely depressed patients is unknown; however, the experience with Venlafaxine Hydrochloride Extended-release Capsules doses higher than 225 mg per day is very limited.
This is a single-institution, open-label, non-randomized phase II trial of erlotinib administered concomitantly with radiation therapy following surgical resection of gross disease. A total of 45 patients with previously unirradiated, high-risk cutaneous SCC requiring post-operative radiotherapy will be enrolled to assess the primary endpoints of time to recurrence and disease free survival. Pretreatment biopsies will be required to confirm the histological diagnosis of SCC. Four to six weeks after surgical resection, patients will begin erlotinib (150 mg po qd) beginning the first day of radiotherapy. Patients will receive 5040 cGy beginning on day 1 of therapy in standard fractionations. Patients will be followed to evaluate for toxicity based on NCI common toxicity criteria (v3.0). Patients will be followed on protocol for a minimum of 2 years with regularly scheduled CT scans, clinical evaluations, and laboratory work. Patients with residual or recurrent cancer will be taken off protocol for salvage therapy.

As a secondary objective, molecular response of tumors to erlotinib monotherapy will be determined. When possible, participants will be enrolled and treated for 14 days with erlotinib prior to surgical resection. The pretreatment biopsy specimen (control) will then be compared to tissue acquired during the surgical resection after 14 days of erlotinib (experimental group).
FIELD: medicine, mycology, dermatology. SUBSTANCE: one should use a solution as antimicrobial product. To prepare this solution it is necessary to grind 14 tablets of lamysil to obtain powder-like state, then they are poured with 100 ml 1%-dimexide solution, the mixture obtained should be kept for 1 d in sealed dark glass-made vial, then 100 ml 70%-acetic acid should be added together with 100 ml 5%-iodine solution. Then the solution obtained should be applied upon nail laminae and nail-walls once daily, and upon feet's skin -twice weekly for 6 mo. The present method leads to higher efficiency of therapy due to increased percentage of clinicolaboratory healing of onychomycosis and prevents the development of disease relapses. EFFECT: improved results of therapy.
Stem cells therapy in the management of soft tissue healing has been shown to be safe and feasible with encouraging short-term results both for crypto glandular and Crohns anal fistula. The long-term results are still insufficient but based on only a few studies conducted with small patient series and various techniques and type of stem cells. In the present study the patient's own adipose tissue derived regenerative cells (ADRCs) will be used. Traditionally the stem cells are injected into the fistula tract; however survival and retaining the stem cells in the fistula tract is problematic. Alternatively, one may apply stem cells enriched fatty tissue around and into the fistula tract. The aim of this project is to develop a method for treatment of patients with Crohns fistula. The results of conventional surgery are disappointing and followed by a high degree of recurrence and complications.
A system and method for a skin treatment lotion. The lotion has a protecting agent, a moisture absorber, a binding agent, water, and an antibiotic agent or hydrocortisone. In one example, the protecting agent is zinc oxide, the moisture absorber is talcum, the binding agent is glycerin, and the antibiotic agent comprises neomycin. The lotion is applied topically to treat skin irritants. In one example, the lotion is stored and dispensed in a dispenser. This allows for controlled dispensing of the lotion as well as preventing the water within the lotion from evaporating.
PURPOSE:To obtain a dental composite material to be uniformly polymerized and cured without kneading, polymerizable and curable only by irradiation with ultrasonic wave, comprising microcapsules prepared 6y coating a polymerization promoter with a film, a polymerizable monomer, a filler and a polymerization initiator. CONSTITUTION:Microcapsules are formed by coating a polymerization promoter (e.g. N,N-dimethyl-p-toluidine) with a film of a polymer prepared by polymerizing a hydrophobic monomer (e.g. polyisocyanate) with a hydrophilic monomer (e.g. polyamine) in water and blended with a polymerizable monomer (e.g. trimethylolpropane trimethacrylate), a filler (e.g. silicon dioxide subjected to surface treatment) and a polymerization initiator (e.g. benzoyl peroxide). A proper amount of the material is taken out, irradiated with ultrasonic wave and the film applied to the polymerization promoter is broken so that the polymerization promoter is activated. Consequently, the monomer starts polymerization and is cured.
Any gender, aged 65 years and over. Chronic kidney disease with eGFR between 15 and 60 ml/min. No immunological cause of kidney disease. Not immunosuppressed. To receive both seasonal influenza and pneumococcal polysaccharide vaccines as part of recommended clinical care.
1. A method for the preparation of citalopram from a compound of formula wherein Y is a cyano group or a group which may be converted to a cyano group, R is hydrogen, -O-R<1>, NH2, NHCH3 or -N(CH3)2 wherein R<1> is selected from hydrogen, alkyl, alkenyl, alkynyl and optionally alkyl substituted aryl or aralkyl, which in either order includes i) reduction of the double bond in the side chain of formula -CH=CH-COR; ii) conversion of the group -COR or a reduced form thereof to a dimethylaminomethyl group; and iii) if Y is not cyano, conversion of the group Y to a cyano group; followed by isolation of citalopram base or a pharmaceutically acceptable acid addition salt thereof. 2. The method according to claim 1 wherein the compound of formula (III) is prepared by reaction of a compound of formula wherein Y is a cyano group or a group which may be converted to a cyano group, with a compound having the formula wherein R is hydrogen, -O-R<1>, -NH2, -NHCH3 or -N(CH3)2 wherein R<1> is selected from hydrogen, alkyl, alkenyl, alkynyl, and optionally alkyl substituted aryl or aralkyl; to form a compound of formula(III). 3. The method according to claim 1, wherein -COR is -CON(CH)3 and the conversion of this group to the dimethylaminomethyl group is carried out by reduction. 4. The method according to claim 1, wherein -COR is -CONHCH3 or -CONH2 and the conversion of these groups is carried out by, in either order, reduction and methylation or reductive amination to form a dimethylaminomethyl group. 5. The method of claim 1 wherein R is-CHO and the conversion to the dimethylaminomethyl group is carried out by reductive amination with dimethylamine or a salt thereof. 6. The method of claim 1 wherein R is-COOR<1> and the conversion to the dimethylaminomethyl group is carried out by conversion to the corresponding amide followed by reduction and optionally methylation or reductive amination to form a dimethylaminomethyl group. 7. The method of claim 1 wherein R is-COOR<1> and the conversion of this group to the dimethylaminomethyl group is carried out by reduction to the corresponding alcohol, followed by conversion of the alcohol group to a feasible leaving group and consecutively reaction a) with dimethylamine or a salt thereof, b) with methylamine followed by methylation or reductive amination to form a dimethylamino group, or c) with an azide followed by reduction to form the corresponding amino compound and thereafter methylation or reductive amination to form a dimethylamino group. 8. A compound having the formula wherein Y is a cyano group or a group which can be converted to a cyano group, R is hydrogen, -O-R<1>, NH2, NHCH3 or -N(CH3)2 wherein R<1> is selected from hydrogen, alkyl, alkenyl, alkynyl and optionally alkyl substituted aryl or aralkyl, or an acid addition salt thereof.